Table 2a. Likelihood of receiving “standard” treatment (surgery) for stage I-II NSCLC.
| Univariate OR (95% CI) |
Univariate P-Value |
Multivariate OR (95% CI) |
Multivariate P-Value |
|
|---|---|---|---|---|
| Age | ||||
| < 65 | Reference | 0.78 | Reference | 0.08 |
| ≥ 65 | 0.91 (.045-1.83) | 0.34 (0.11-1.12) | ||
| Gender | ||||
| Male | Reference | 0.59 | Reference | 0.83 |
| Female | 1.21 (0.61-2.42) | 1.08 (0.51-2.30) | ||
| Race | ||||
| White, non-Hispanic | Reference | 0.01 | Reference | 0.17 |
| Other | 0.41(0.20-0.82) | 0.56 (0.24-1.29) | ||
| Insurance | ||||
| Private | Reference | <0.001 | Reference | 0.001 |
| Medicare | 0.48 (0.17-1.36) | 0.76 (0.20-2.86) | ||
| Indigent | 0.13 (0.05-0.40) | 0.13 (0.04-0.43) | ||
| Stage | ||||
| Stage I | Reference | 0.01 | Reference | 0.03 |
| Stage II | 0.39 (0.19-0.83) | 0.40 (0.17-0.92) | ||
| Histology | ||||
| Adenocarcinoma | Reference | 0.09 | Reference | 0.28 |
| Squamous Cell | 0.44 (0.21-0.94) | 0.51 (0.23-1.17) | ||
| Other * | 0.51 (0.18-1.44) | 0.78 (0.25-2.47) |
*
Includes patients with large cell, adenosquamous or unspecified